Cloning, expression and purification of the factor H binding protein and its interaction with factor H

Fatemeh Yarian1, Mojgan Bandehpour2,3*, Negar Seyed4, Bahram Kazemi1,2,3

1Department of Biotechnology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran

ABSTRACT

Background and Objective: Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. The factor H binding protein (fHBP) is a key virulence factor of Neisseria meningitidis that is able to selectively bind to human factor H, the key regulator of the alternative complement pathway, which it has important implications for meningococcal pathogenesis and vaccine design. The aims of present research were cloning, expression, purification of fHbp and confirmation of the interaction between serum factor H (fH) and produced factor H binding protein.

Materials and Methods: A 820 base pairs fhbp gene fragment was amplified by PCR and cloned into expression vector pET28a (+) in Bam HI and SalI restriction enzymes sites. Recombinant DNA was expressed in BL21 (DE3) cell. fHBP protein was purified by Ni-NTA agarose resin. Coupling of recombinant protein into CNBr activated Sepharose 4B resin was carried out for application in serum fH protein purification. (fH-fHBP) interaction was confirmed by SDS-PAGE and far-western blotting.

Results and Conclusions: SDS-PAGE results showed a 35 kDa protein band. 150 kDa fH protein was purified by designed Sepharose 4B resin. Far-western blotting confirmed (fH-fHBP) interaction and proper folding of factor H binding protein.

Keywords: N. meningitidis, FHB, Cloning, FH protein, Far-western blotting.

INTRODUCTION

Neisseria meningitidis is a Gram-negative microorganism and an exclusive human pathogen that usually exists in an asymptomatic nasopharyngeal carriage state. However, N. meningitidis can cause devastating invasive disease, such as septicemia or meningitis, following penetration of the mucosal tissue, invasion of the bloodstream, and colonization of the meninges. The virulence of N. meningitidis is influenced by multiple factors: capsule polysaccharide and surface adhesive proteins expression (outer membrane proteins including pili, porins PorA and B, adhesion molecules Opa and Opc), iron sequestration mechanisms, and endotoxin...
gosaccharide, LOS) (1). fHBP was initially identified as a surface-exposed lipoprotein with unknown function named GNA1870 (genome-derived Neisseria antigen 1870) (2). The complement system plays an important role in innate immune defense against pathogenic microbes. Factor H is a 150-kDa soluble protein that is the main regulator of the alternative pathway (AP) which it is secreted in the nasopharynx (3). Some microbes and viral pathogens such as Echinococcus granulosus, Onchocerca volvulus and HIV, avoid complement-mediated killing system by recruiting fH to their surfaces (4). Pioneering study demonstrated that the interaction of fH with the meningococcus GNA1870 (fHBP) is the principal of fH-binding meningococcal protein (5). Most (fH-fHBP) interaction studies have been done in vivo (5). Therefore we attempted to produce recombinant fHBP and investigate it in vitro. All together the production of recombinant proteins are one of the biotechnology special skills for drug or vaccine and nutrition science researches. Currently, recombinant proteins are found fundamentally in every medical testing and biological research laboratory (6). So the recombinant fHBP will be applied in medical sciences like the design of diagnostic kit or meningococcus vaccine preparation.

MATERIALS AND METHODS

Cloning of fHBP gene into pET 28a (+). The fhbp gene was selected based on the fhbp gene sequence in the GenBank accession nos. ACA52540.1. It was synthesized into pGH plasmid (Bioneer, Korea). The fhbp gene was amplified from pGH plasmid by specific primers. Amplification was carried out in 30 cycles of 40 sec at 94 °C, 40 sec at 64 °C and 1 min at 72 °C. The PCR product was confirmed by nucleic acid sequencing. Following the initial confirmation, PCR product and pET28a (+) (Novagen, USA) were digested with BamHI and SalI (Fermentas, Lithuania). Ligation was carried out with T4 DNA Ligase (Fermentas, Lithuania). The ligation reaction was transformed into E. coli Top10 competent cell (7). The recombinant plasmids were confirmed by colony PCR and restriction enzyme analysis.

Expression of the recombinant fhbp gene. E. coli BL21 (DE3) was used for protein expression as host with 50μg/μl kanamycin (Merck,Germany) in LB medium for selection, 0.5 mM IPTG (Isopropyl-beta-D-thiogalacto-pyranoside) (Merck,Germany) as inducer. Samples were collected 3, 5, 7, and 9 hours after induction. The cells were harvested, treated with lysis buffer (50 mM Tris base, 10% glycerol, 0.1% Triton X-100) (Merck, Germany) and the lysate was analyzed by SDS-PAGE and the quantity of the expressed protein was estimated by comparing the intensity of the protein bands.

Western blot analysis. Proteins resolved by SDS-PAGE were electrophoretically transferred to a nitrocellulose membrane (Wathman, UK). TBS buffer (Tris-Buffered Saline containing 3% BSA (Bovine Serum Albumin) (Sigma, USA) was used for blocking the membrane. The membrane immersed in 1:2000 dilution of ALP (alkaline phosphatase) conjugated anti His-tag monoclonal antibody (Abcam, UK) 2 hours at room temperature. Subsequently, it was visualized for color after development in NBT/BCIP substrate solution (Roche, Germany).

Purification of the protein. The recombinant protein purification was carried out by Ni-NTA column as specified by the manufacturer's instructions (Novagen, USA). The purified protein was subsequently analyzed by SDS-PAGE and western blotting using anti His-tag antibody.

Coupling of recombinant protein into CNBr activated Sepharose 4B and purification of fH serum protein. For studying of (fH-fHBP) interaction, purified fHbp protein was coupled to CNBr activated Sepharose 4B by the manufacturer's instructions (Novagen, USA). 500 µl of human serum was dialyzed by coupling buffer (NaHCO3 0.1 M, NaCl 0.5 M, PH 8). The affinity chromatography was performed for isolation of fH protein from serum sample. It was eluted by two different pH buffer (Glycin,NaCl, pH:2 and Diethanolamin,NaCl pH:11) (Merck, Germany).

Far Western blot analysis. The human serum proteins as factor H source, was separated under non-reducing conditions by 10% SDS-PAGE. The protein bands transferred to nitrocellulose membrane. After membrane blocking with 5% skim milk, the blots were immersed for 2 hours in purified buffered fHBP (PBS/0.5%Tween20/0.5% skim milk).
milk). The eluted factor H was analyzed by western blotting using an ALP-conjugated anti-His tag antibody (Abcam, UK) (8).

RESULTS

The preparation of gene fragment. The fhbp gene was amplified with specific primers as shown in Fig. 1. The pET28a/fHBP plasmid was confirmed by specific PCR, universal PCR and restriction analysis (Fig. 2).

Expression of fHBP recombinant protein. Recombinant protein expression was confirmed by western blotting (Fig. 3A). The optimum incubation time after induction was considered 3 hours (Fig. 3B).

Purification of the recombinant protein. Purification of the recombinant protein was carried out using Ni-NTA affinity column (Fig. 4A). The expected protein band was obtained in eluted fraction and confirmed by western blotting (Fig. 4B).

Purification of serum fH protein. Serum factor H protein was purified using CNBr activated Sepharose 4B coupled to fHBP. It was analyzed by SDS-PAGE and a ≈150 KD protein was detected (Fig. 5).
Fig. 3. SDS-PAGE and Western blot analysis of the recombinant protein expression at different times: (A) Lane M, molecular weight marker; Lane 1, BL 21; Lane 2, 0 time; Lane 3, 3h after induction. (B) Lane 1, 3h; Lane 2, 5h; Lane 3, 7h after induction with 0.5 mM IPTG. Lane 4, BL 21 cell; Lane 5, 0 time.

Fig. 4. SDS-PAGE and Western blot analysis of the purified recombinant protein after purification: (A) Lane 1, purified protein; 2; Lane M, molecular weight marker; Lane 3, bacterial lysate after 3h incubation. (B) Lane 1, purified protein; Lane M, molecular weight marker; Lane 2, BL 21 cell lysate.
**DISCUSSION**

*Neisseria meningitidis* is an obligate human pathogen and important cause of septicemia and meningitis that it is known a major cause of morbidity and mortality worldwide. To cause disease, the bacterium must successfully survive in the bloodstream where it has to avoid being killed by host innate immune mechanisms, particularly the complement system (9). Most *N. meningitidis* strains studied to date, express fHBP, with levels of expression that vary significantly among isolates (2). Humans clear meningococci via both the classical and alternative complement pathways (10). Factor H is a 150-kDa glycoprotein typically presents in human plasma at concentrations of 300 to 500 μg/ml (11). fH is the main inhibitor of the alternative complement pathway and a key discriminator between host and pathogen cells. Many pathogens, however, have evolved to evade this alternative complement pathway by binding fH on the bacterial surface. Although fH binding proteins have been identified in many pathogens, the sequence and structure of fHBP are unique to *N. meningitidis* and a few other neisserial species (12). Interestingly, fHBP only binds human fH, which may be one explanation of the species-specificity of meningococci for the human host (13). The ability of fHBP to bind human fH with high affinity has implications not only for its role as a
virulence factor in vivo, but also it can be as a target antigen for vaccination against meningococcus. Anti-fHBP antibodies can elicit protection by two mechanisms: direct complement-mediated killing of the bacterium and blocking fH binding to the bacteria to increase the susceptibility of the bacterium to be killed by the alternative complement pathway (5). Several studies have shown that inhibition of fH binding to fHBP results in increased susceptibility of the bacteria to complement-mediated bactericidal activity (14). The main objective of present study was producing of recombinant fHBP and fH-fHBP interaction study in vitro. Confirmation of this step, can be used in the field of vaccine and specific antibodies production. Prokaryotic systems are powerful tools for production of this recombinant protein. Escherichia coli is one of the best micro organisms of choice in this field. It is a factory and well-established micro organism for the most popular expression platform. Recombinant DNA is extensively used in biotechnology, medicine and researches (15). For this reason, pET expression system has been developed for the cloning and expression of recombinant proteins in E. coli based on the T7 promoter (16). So, successful sub cloning of 820 bp fHBP gene into pET 28a (+) expression vector was carried out by enzymatic digestion. Western blotting technique using Anti-6X His-tag antibody confirmed 35 kDa molecular mass recombinant protein expression. Purified protein by Ni-NTA agarose resin showed two distinct monomer and dimer bands on gel and western blotting. There were two ways to check (fH-fHbp) interaction. One of them was designing of new affinity chromatography which resin binds to recombinant fHBP. CNBr activated Sepharose 4B is able to coupling with some proteins. Therefore, by activation of resin according to manufacturer’s protocol, fHbp was coupled into resin. fH is a ligand for fHBP (5) and it has typically 150-kDa glycoprotein presents in human serum at concentrations of 300 to 500 μg/ml (11, 17). Because of unique structure of this recombinant protein and specific coupling condition, its purification will be very specific. Rickard Nilsson in 2013 described an affinity chromatography column to purify a large amount of recombinant fH protein. It was used Far-Western blotting. In present study, human serum fH protein was used as a prey protein and purified recombinant fHBP as a bait one. Recombinant fHBP consists of 6X-His tag peptid, which is detectable with conjugated Anti-6X His-tag antibody. Based on the results of this study, considerable amount of recombinant fHbp protein was expressed in E. coli BL21 (DE3). It was used for designing a proper chromatography column to purify a large amount of the factor H protein.

ACKNOWLEDGEMENT

This article was extracted from Fatemeh Yarian’s thesis and was carried out in Cellular and Molecular Biology Research Center of Shahid Beheshti University of Medical Sciences. We thanks Iran National Science Foundation for supporting of this research.

REFERENCES

1. Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine 2009;27 Suppl 2:B71-7.
2. Massignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197:789-99.
3. Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S. The factor H protein family. Immunopharmacology 1999;42(1-3):53-60.
4. Diaz A, Ferreira A, Sim RB. Complement evasion by Echinococcus granulosus: sequestration of host factor
H in the hydatid cyst wall. *J Immunol* 1997;158:3779-3786.

5. Madico G, Welsch JA, Lewis LA, MeNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. *J Immunol* 2006;177:501-510.

6. Sreenivas S, Krishnaiah SM, Govindappa N, Basavaruju Y, Kanojia K, Mallikarjun N, et al. Enhancement in production of recombinant two-chain Insulin Glargine by over-expression of Kex2 protease in Pichia pastoris. *Appl Microbiol Biotechnol* 2015;99:327-336.

7. Ghodsi S, Gharavi S, Ghadam P. Cloning the hbs gene from Bacillus subtilis and expression of the HBsu protein in *Escherichia coli*. *Iran J Microbiol* 2010;2(3):152-6.

8. Nilsson OR, Lannergard J, Morgan BP, Lindahl G, Gustafsson MC. Affinity purification of human factor H on polypeptides derived from streptococcal m protein: enrichment of the Y402 variant. *PloS one* 2013;8(11):e81303.

9. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and *Neisseria meningitidis*. *Lancet* 2007;369(9580):2196-2210.

10. Wright V, Hibberd M, Levin M. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. *Vaccine* 2009;27 Suppl 2:B90-102.

11. Haralambous E, Dolly SO, Hibberd ML, Litt DJ, Udalova IA, O'Dwyer C, et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. *Scand J Infect Dis* 2006;38:764-771.

12. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. *Nat Rev Microbiol* 2008;6:132-142.

13. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to *Neisseria meningitidis* is specific for human fH and inhibits complement activation by rat and rabbit sera. *Infect Immun* 2009;77:764-769.

14. Giuntini S, Beernink PT, Reason DC, Granoff DM. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. *PloS one* 2012;7(3):e34272.

15. Chou CP. Engineering cell physiology to enhance recombinant protein production in *Escherichia coli*. *Appl Microbiol Biotechnol*. 2007;76:521-32.

16. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J Mol Biol* 1986;189:113-130.

17. Pio R, Elsasser TH, Martinez A, Cuttitta F. Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. *Microsc Res Tech* 2002;57:23-27.

18. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. *J Immunol* 2006;176:7566-775.

19. Berggard T, Linse S, James P. Methods for the detection and analysis of protein-protein interactions. *Proteomics* 2007;7:2833-2842.

20. Ohba T, Ishino M, Aoto H, Sasaki T. Dot far-western blot analysis of relative binding affinities of the Src homology 3 domains of Efs and its related proteins. *Anal Biochem* 1998;262:185-192.